Abstract

Background: Vaccines have played a critical role in the prevention and treatment of infectious diseases, greatly lowering worldwide morbidity and mortality. This review examines many forms of vaccinations. In contrast, inactivated vaccines, such as the polio vaccine, are safer for immunocompromised people, they frequently require booster shots. Aim: This review emphasises the importance of vaccinations in public health and the need for innovation to tackle future infectious disease threats. The introduction of new pathogens has prompted the creation of novel vaccination platforms, including mRNA and viral vector vaccines. mRNA vaccines, such as those used to treat COVID-19, use genetic instructions to direct cells to manufacture antigens, resulting in strong immunity. Conclusion: These vaccines have demonstrated excellent efficacy and rapid scaling, making them valuable instruments in pandemics. This review emphasises the necessity of designing vaccine methods that meet individual illnesses, demographics, and logistical obstacles. While vaccinations have considerably reduced the occurrence of infectious diseases, more research is needed to address future threats, improve vaccine efficacy, and overcome obstacles such as vaccine reluctance and global inequities. Understanding the capabilities and limits of each vaccine type will help researchers and policymakers better equip healthcare systems to address current and future infectious disease concerns.

• 1.   Baafi J., Darko I.O., Asenso F.W. Vaccination as a control of infectious diseases. J Appl Computat Math. 2017; 6(357):
• 2.   Excler J.L., Saville M., Berkley S., Kim J.H. Vaccine development for emerging infectious diseases. Nature medicine. 2021 Apr;27(4):591-600.
• 3.   Ghattas M., Dwivedi G., Lavertu M., Alameh M.G. Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines. 2021 Dec 16;9(12):1490.
• 4.   Rodrigues C.M., Plotkin S.A. Impact of vaccines; health, economic and social perspectives. Frontiers in microbiology. 2020 Jul 14; 11:1526.
• 5.   elochukwu ic, okoro o, unekwe p, irinmwinuwa e. role of vaccines in prevention of diseases: a review.
• 6.   Berkeley S. improving access to vaccine through tiered piercing. Lancet 383, 2018: 2256-2267.
• 7.   Saleh A., Qamar S., Tekin A., Singh R., Kashyap R. Vaccine development throughout history. Cureus. 2021 Jul; 13(7).
• 8.   Wever P.C., van Bergen L. Prevention of tetanus during the First World War. Med Humanit. 2012; 38(2):78-82.
• 9.   Rappuoli R., Malito E. History of Diphtheria Vaccine Development. Corynebacterium diphtheriae and Related Toxigenic Specie. Springer; 2014. p. 225-38.
• 10.   Tahamtan A., Charostad J., Shokouh S.J., Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. Journal of Archives in Military Medicine. 2017 Sep 30; 5(3).
• 11.   Conceição Silva F., De Luca P.M., Lima-Junior J.D. Vaccine development against infectious diseases: State of the art, new insights, and future directions. Vaccines. 2023 Oct 25; 11(11):1632.
• 12.   Kumar R. New trends in vaccine characterization, formulations, and development. Vaccines. 2024 Mar 20; 12(3):338.
• 13.   Shapiro C.G., Kendrick P., Grace E. Pertussis vaccines emerging infectious; Journal of medicine, 339(4), 2010; 209-215.
• 14.   Lotfi H., Mazar M.G., Ei N.M., Fahim M., Yazdi NS. Vaccination is the most effective and best way to avoid the disease of COVID-19. Immunity, Inflammation and Disease. 2023 Aug; 11(8):e946.
• 15.   Mak T.W., Saunders M.E. 23—Vaccines and Clinical Immunization. In: Mak T.W., Saunders M.E., editors. The Immune Response. Academic Press; Burlington, MA, USA: 2006. pp. 695–749.
• 16.   Nooraei S., Bahrulolum H., Hoseini Z.S., Katalani C., Hajizade A., Easton A.J., Ahmadian G. Viruslike Particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnology. 2021;19:59.
• 17.   Ding X., Liu D., Booth G., Gao W., Lu Y. Viruslike Particle Engineering: From Rational Design to Versatile Applications. Biotechnol. J. 2018; 13:1700324.
• 18.   Lua L.H.L., Connors N.K., Sainsbury F., Chuan Y.P., Wibowo N., Middelberg A.P.J. Bioengineering Virus-like Particles as vaccines. Biotechnol. Bioeng. 2014; 111:425–440.
• 19.   Makela PH. DEVELOPING VACCINES FOR PREVENTION OF CHRONIC DISEASE. In The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary 2004 Jun 16 (p. 175). National Academies Press.
• 20.   Smith K. Vaccines and chronic disease. Delaware Journal of Public Health. 2017 Mar;3(1):46.
• 21.   Rodrigues C.M., Plotkin S.A. Impact of vaccines; health, economic and social perspective. Frontiers in microbiology. 2020 Jul 14;11:1526.
• 22.   Hajizade A., Ebrahimi F., Salmanian A.H., Arpanaei A., Amani J. Nanoparticles in vaccine development. Journal of Applied Biotechnology Reports. 2014 Dec 1; 1(4):125-34.
• 23.   S. Nooraei et al., “Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers,” J. Nanobiotechnology, vol. 19, no. 1, Dec. 2021.
• 24.   I. Ielo, G. Rando, F. Giacobello, S. Sfameni, A. C.- Molecules, and undefined 2021, “Synthesis, chemical–physical characterization, and biomedical applications of functional gold nanoparticles: A review,” mdpi.comI Ielo, G Rando, F. Giacobello, S. Sfameni, A. Castellano, M Gall. D. Drommi, G. Rosacea Molecules, 2021.
• 25.   Pollard, A.J., Perrett, K.P., and Beverley, P.C. (2009). Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213–220.
• 26.   Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Kuriyakose, S., Leyssen, M., et al. (2011). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J. Viral Hepat. 18, 369–375.
• 27.   Riumallo-Herl, C., Chang, A.Y., Clark, S., Constenla, D., Clark, A., Brenzel, L., et al. (2018). Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. BMJ Glob. Health 3:e000613.
• 28.   Soergel, P., Makowski, L., Schippert, C., Staboulidou, I., Hille, U., and Hillemanns, P. (2012). The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum. Vacc. Immunother. 8, 243–251.

Data Sharing Statement

Funding